@article{ref1,
title="Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States",
journal="Journal of the American Academy of Dermatology",
year="2016",
author="Danesh, Melissa J. and Kimball, Alexa B.",
volume="74",
number="1",
pages="190-192",
abstract="<p>Brodalumab is a human monoclonal antibody developed by Amgen, Inc. to treat inflammatory diseases. In May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having &quot;events of suicidal ideation and behavior&quot;...</p> <p>Language: en</p>",
language="en",
issn="0190-9622",
doi="10.1016/j.jaad.2015.08.057",
url="http://dx.doi.org/10.1016/j.jaad.2015.08.057"
}